Propionibacterium acnes camp factor and host acid sphingomyelinase contribute to bacterial virulence: Potential targets for inflammatory acne treatment

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Nakatsuji, Teruaki ^a,b   Tang, De chu C ^c   Zhang, Liangfang ^d   Gallo, Richard L ^a,b   Huang, Chun Ming ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c Vaxin Incorporated   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID SPHINGOMYELINASE ANTIBODY; ANTIBODY; CD11B ANTIGEN; CHRISTIE ATKINS MUNCH PETERSON FACTOR; DESIPRAMINE; IMMUNOGLOBULIN G ANTIBODY; SECRETORY PROTEIN; SPHINGOMYELIN PHOSPHODIESTERASE; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; DERMATOLOGICAL AGENT;

ACNE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BACTERIAL VIRULENCE; CELL DEATH; CELL INFILTRATION; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; EAR SWELLING; FEMALE; HEMOLYSIS; HUMAN; HUMAN CELL; IMMUNOGENICITY; KERATINOCYTE; MACROPHAGE; MOUSE; NONHUMAN; OTITIS; PROPIONIBACTERIUM ACNES; SWELLING; ACNE VULGARIS; ANIMAL; CBA MOUSE; CELL LINE; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PHYSIOLOGY; VIRULENCE;

BACTERIA (MICROORGANISMS); MUS; PROPIONIBACTERIUM ACNES;

ACNE VULGARIS; ANIMALS; BACTERIAL PROTEINS; CELL LINE; DERMATOLOGIC AGENTS; DESIPRAMINE; HUMANS; MICE; MICE, INBRED CBA; PROPIONIBACTERIUM ACNES; SPHINGOMYELIN PHOSPHODIESTERASE; VIRULENCE;

EID: 79954455303     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014797     Document Type: Article

References (66)

1. Cunliffe WJ, Gollnick HP, (2001) Microbiology of acne. In: Cunliffe WJ, Gollnick HP, editors. Acne Martin Dunitz pp. 29-36.
2. Leeming JP, Holland KT, Cuncliffe WJ, (1988) The microbial colonization of inflamed acne vulgaris lesions. Br J Dermatol 118: 203-208.
3. Leyden JJ, McGinley KJ, Vowels B, (1998) Propionibacterium acnes colonization in acne and nonacne. Dermatology 196: 55-58.
4. Chavant P, Gaillard-Martinie B, Hebraud M, (2004) Antimicrobial effects of sanitizers against planktonic and sessile Listeria monocytogenes cells according to the growth phase. FEMS Microbiol Lett 236: 241-248.
5. Kligman AM, (1974) An overview of acne. J Invest Dermatol 62: 268-287.
6. Toyoda M, Morohashi M, (2001) Pathogenesis of acne. Med Electron Microsc 34: 29-40.
7. Degitz K, Placzek M, Borelli C, Plewig G, (2007) Pathophysiology of acne. J Dtsch Dermatol Ges 5: 316-323.
8. Kim J, (2005) Review of the innate immune response in acne vulgaris: activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses. Dermatology 211: 193-198.
9. Kim J, Ochoa MT, Krutzik SR, Takeuchi O, Uematsu S, et al. (2002) Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 169: 1535-1541.
10. Nagy I, Pivarcsi A, Kis K, Koreck A, Bodai L, et al. (2006) Propionibacterium acnes and lipopolysaccharide induce the expression of antimicrobial peptides and proinflammatory cytokines/chemokines in human sebocytes. Microbes Infect 8: 2195-2205.
11. Rowe GE, Welch RA, (1994) Assays of hemolytic toxins. Methods Enzymol 235: 657-667.
12. Choudhury TK, (1978) Synergistic lysis of erythrocytes by Propionibacterium acnes. J Clin Microbiol 8: 238-241.
13. Christie R, Atkins NE, Munch-Petersen E, (1944) A note on a lytic phenomenon shown by group B streptococci. Aust J Exp Biol Med Sci 22: 197-200.
14. Lang S, Palmer M, (2003) Characterization of Streptococcus agalactiae CAMP factor as a pore-forming toxin. J Biol Chem 278: 38167-38173.
15. Litwin CM, Johnson JM, (2005) Identification, cloning, and expression of the CAMP-like factor autotransporter gene (cfa) of Bartonella henselae. Infect Immun 73: 4205-4213.
16. Bruggemann H, (2005) Insights in the pathogenic potential of Propionibacterium acnes from its complete genome. Semin Cutan Med Surg 24: 67-72.
17. Rosen T, (2007) The Propionibacterium acnes genome: from the laboratory to the clinic. J Drugs Dermatol 6: 582-586.
18. Bruggemann H, Henne A, Hoster F, Liesegang H, Wiezer A, et al. (2004) The complete genome sequence of Propionibacterium acnes, a commensal of human skin. Science 305: 671-673.
19. Valanne S, McDowell A, Ramage G, Tunney MM, Einarsson GG, et al. (2005) CAMP factor homologues in Propionibacterium acnes: a new protein family differentially expressed by types I and II. Microbiology 151: 1369-1379.
20. Brown J, Farnsworth R, Wannamaker LW, Johnson DW, (1974) CAMP factor of group B streptococci: production, assay, and neutralization by sera from immunized rabbits and experimentally infected cows. Infect Immun 9: 377-383.
21. Jiang M, Babiuk LA, Potter AA, (1996) Cloning, sequencing and expression of the CAMP factor gene of Streptococcus uberis. Microb Pathog 20: 297-307.
22. Jurgens D, Sterzik B, Fehrenbach FJ, (1987) Unspecific binding of group B streptococcal cocytolysin (CAMP factor) to immunoglobulins and its possible role in pathogenicity. J Exp Med 165: 720-732.
23. El-Huneidi W, Mui R, Zhang TH, Palmer M, (2007) Streptococcus agalactiae CAMP factor/protein B does not bind to human IgG. Med Microbiol Immunol 196: 73-77.
24. Hensler ME, Quach D, Hsieh CJ, Doran KS, Nizet V, (2008) CAMP factor is not essential for systemic virulence of Group B Streptococcus. Microb Pathog 44: 84-88.
25. Bernard P, (2008) Management of common bacterial infections of the skin. Curr Opin Infect Dis 21: 122-128.
26. Till AE, Goulden V, Cunliffe WJ, Holland KT, (2000) The cutaneous microflora of adolescent, persistent and late-onset acne patients does not differ. Br J Dermatol 142: 885-892.
27. Levade T, Jaffrezou JP, (1999) Signalling sphingomyelinases: which, where, how and why? Biochim Biophys Acta 1438: 1-17.
28. Clarke CJ, Snook CF, Tani M, Matmati N, Marchesini N, et al. (2006) The extended family of neutral sphingomyelinases. Biochemistry 45: 11247-11256.
29. Goni FM, Alonso A, (2002) Sphingomyelinases: enzymology and membrane activity. FEBS Lett 531: 38-46.
30. Stoffel W, (1999) Functional analysis of acid and neutral sphingomyelinases in vitro and in vivo. Chem Phys Lipids 102: 107-121.
31. Lang S, Xue J, Guo Z, Palmer M, (2007) Streptococcus agalactiae CAMP factor binds to GPI-anchored proteins. Med Microbiol Immunol 196: 1-10.
32. Skalka B, Smola J, (1981) Lethal effect of CAMP-factor and UBERIS-factor-a new finding about diffusible exosubstances of Streptococcus agalactiae and Streptococcus uberis. Zentralbl Bakteriol A 249: 190-194.
33. Nakatsuji T, Shi Y, Zhu W, Huang CP, Chen YR, et al. (2008) Bioengineering a humanized acne microenvironment model: proteomics analysis of host responses to Propionibacterium acnes infection in vivo. Proteomics 8: 3406-3415.
34. Tomiuk S, Hofmann K, Nix M, Zumbansen M, Stoffel W, (1998) Cloned mammalian neutral sphingomyelinase: functions in sphingolipid signaling? Proc Natl Acad Sci U S A 95: 3638-3643.
35. Marchesini N, Hannun YA, (2004) Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem Cell Biol 82: 27-44.
36. Otterbach B, Stoffel W, (1995) Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick disease). Cell 81: 1053-1061.
37. Hofmann K, Dixit VM, (1998) Ceramide in apoptosis-does it really matter? Trends Biochem Sci 23: 374-377.
38. Yang J, Yu Y, Sun S, Duerksen-Hughes PJ, (2004) Ceramide and other sphingolipids in cellular responses. Cell Biochem Biophys 40: 323-350.
39. Utermohlen O, Herz J, Schramm M, Kronke M, (2008) Fusogenicity of membranes: the impact of acid sphingomyelinase on innate immune responses. Immunobiology 213: 307-314.
40. Albouz S, Le Saux F, Wenger D, Hauw JJ, Baumann N, (1986) Modifications of sphingomyelin and phosphatidylcholine metabolism by tricyclic antidepressants and phenothiazines. Life Sci 38: 357-363.
41. Albouz S, Hauw JJ, Berwald-Netter Y, Boutry JM, Bourdon R, et al. (1981) Tricyclic antidepressants induce sphingomyelinase deficiency in fibroblast and neuroblastoma cell cultures. Biomedicine 35: 218-220.
42. Hurwitz R, Ferlinz K, Sandhoff K, (1994) The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol Chem Hoppe Seyler 375: 447-450.
43. Wu X, Shen Z, Zeng X, Lang S, Palmer M, et al. (2008) Synthesis and biological evaluation of sperm CD52 GPI anchor and related derivatives as binding receptors of pore-forming CAMP factor. Carbohydr Res 343: 1718-1729.
44. Nagafuku M, Kabayama K, Oka D, Kato A, Tani-ichi S, et al. (2003) Reduction of glycosphingolipid levels in lipid rafts affects the expression state and function of glycosylphosphatidylinositol-anchored proteins but does not impair signal transduction via the T cell receptor. J Biol Chem 278: 51920-51927.
45. Englund PT, (1993) The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors. Annu Rev Biochem 62: 121-138.
46. De Young LM, Spires DA, Ballaron SJ, Cummins CS, Young JM, et al. (1985) Acne-like chronic inflammatory activity of Propionibacterium acnes preparations in an animal model: correlation with ability to stimulate the reticuloendothelial system. J Invest Dermatol 85: 255-258.
47. De Young LM, Young JM, Ballaron SJ, Spires DA, Puhvel SM, (1984) Intradermal injection of Propionibacterium acnes: a model of inflammation relevant to acne. J Invest Dermatol 83: 394-398.
48. Webster GF, Leyden JJ, Musson RA, Douglas SD, (1985) Susceptibility of Propionibacterium acnes to killing and degradation by human neutrophils and monocytes in vitro. Infect Immun 49: 116-121.
49. Liu GY, Doran KS, Lawrence T, Turkson N, Puliti M, et al. (2004) Sword and shield: linked group B streptococcal beta-hemolysin/cytolysin and carotenoid pigment function to subvert host phagocyte defense. Proc Natl Acad Sci U S A 101: 14491-14496.
50. Schnupf P, Portnoy DA, (2007) Listeriolysin O: a phagosome-specific lysin. Microbes Infect 9: 1176-1187.
51. McCollister BD, Myers JT, Jones-Carson J, Voelker DR, Vazquez-Torres A, (2007) Constitutive acid sphingomyelinase enhances early and late macrophage killing of Salmonella enterica serovar Typhimurium. Infect Immun 75: 5346-5352.
52. Utermohlen O, Karow U, Lohler J, Kronke M, (2003) Severe impairment in early host defense against Listeria monocytogenes in mice deficient in acid sphingomyelinase. J Immunol 170: 2621-2628.
53. Schramm M, Herz J, Haas A, Kronke M, Utermohlen O, (2008) Acid sphingomyelinase is required for efficient phago-lysosomal fusion. Cell Microbiol.
54. Nakatsuji T, Liu YT, Huang CP, Gallo RL, Huang CM, (2008) Antibodies elicited by inactivated Propionibacterium acnes-based vaccines exert protective immunity and attenuate the IL-8 production in human sebocytes: relevance to therapy for acne vulgaris. J Invest Dermatol 128: 2451-2457.
55. Nakatsuji T, Liu YT, Huang CP, Gallo RL, Huang CM, (2008) Vaccination targeting a surface sialidase of P. acnes: implication for new treatment of acne vulgaris. PLoS ONE 3: e1551.
56. Perry AL, Lambert PA, (2006) Propionibacterium acnes. Lett Appl Microbiol 42: 185-188.
57. Kobayashi F, Nagoya T, Koshi T, Saino Y, (1980) Biphasic protection against bacterial infection in mice induced by vaccination of Propionibacterium acnes. Infect Immun 27: 391-396.
58. Rasko DA, Moreira CG, Li de R, Reading NC, Ritchie JM, et al. (2008) Targeting QseC signaling and virulence for antibiotic development. Science 321: 1078-1080.
59. Haider A, Shaw JC, (2004) Treatment of acne vulgaris. Jama 292: 726-735.
60. Nakatsuji T, Kao MC, Fang JY, Zouboulis CC, Zhang L, et al. (2009) Antimicrobial Property of Lauric Acid Against Propionibacterium Acnes: Its Therapeutic Potential for Inflammatory Acne Vulgaris. J Invest Dermatol.
61. Martin A, Clynes M, (1993) Comparison of 5 microplate colorimetric assays for in vitro cytotoxicity testing and cell proliferation assays. Cytotechnology 11: 49-58.
62. Smith JP, Durfee KK, Marymont JH Jr, (1979) A review of laboratory methods for identification of group B streptococci (Streptococcus agalactiae). Am J Med Technol 45: 199-204.
63. Liu YT, Lin SB, Huang CP, Huang CM, (2008) A novel immunogenic spore coat-associated protein in Bacillus anthracis: characterization via proteomics approaches and a vector-based vaccine system. Protein Expr Purif 57: 72-80.
64. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, et al. (1988) Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106: 761-771.
65. Martin A, Clynes M, (1991) Acid phosphatase: endpoint for in vitro toxicity tests. In Vitro Cell Dev Biol 27A: 183-184.
66. Kratochwil NA, Huber W, Muller F, Kansy M, Gerber PR, (2002) Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol 64: 1355-1374.